Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | BCL9 | O00512 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406332 | 0.93 | HTR2A (0.49) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL15459741 | 0.90 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL2235530 | 0.87 | HTR2A (0.54) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL7989561 | 0.87 | HTR2A (0.53) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL2233848 | 0.86 | HTR2A (0.50) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL1036489 | 0.85 | HTR2A (0.52) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL23202970 | 0.85 | HTR2A (0.49) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL8605685 | 0.85 | HTR2A (0.49) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL23203128 | 0.85 | HTR2A (0.49) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL2235137 | 0.85 | BCL9 (0.56) | HTR2AGAABCL9CTNNB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242059-B1 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIV NORTH CAROLINA (US) | 2007-03-21 | — | — | EP | claimed |
| US-6649652-B2 | Hypotensive agents; hyperglycemic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-11-18 | — | — | US | claimed |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | claimed |
| EP-1242059-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001003685-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-01-18 | — | — | WO | claimed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-3860999-B9 | DERIVATIVES OF RELEBACTAM AND USES THEREOF | ARIXA PHARMACEUTICALS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-0584694-A1 | Imidazolidin derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-02 | — | — | EP | disclosed |
| EP-0465481-B1 | NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN | LEPETIT SPA (IT) | 1993-11-18 | — | — | EP | disclosed |
| EP-0465481-A1 | NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN. | LEPETIT SPA (IT) | 1992-01-15 | — | — | EP | disclosed |
| WO-1990011300-A1 | NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN | GRUPPO LEPETIT S.P.A. (IT) | 1990-10-04 | — | — | WO | disclosed |
| EP-0167451-B1 | A NEW PROCESS FOR PREPARING NOVEL N-(ACYLOXY-ALKOXY) CARBONYL DERIVATIVES USEFUL AS BIOREVERSIBLE PRODRUG MOIETIES FOR PRIMARY AND SECONDARY AMINE FUNCTIONS IN DRUGS | MERCK & CO. INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0381661-A1 | 1-E3-(2-hydroxy-3-alkylaminopropoxy)-2-thienyl]-3-phenyl-1-propanon and process for its preparation | Laevosan-Gesellschaft m.b.H. (AT) | 1990-08-08 | — | — | EP | disclosed |
| US-4916230-A | Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs | MERCK & CO., INC. (US) | 1990-04-10 | — | — | US | disclosed |
| EP-0167451-A2 | A new process for preparing novel N-(acyloxy-alkoxy) carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs | MERCK & CO. INC. (US) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | HTR2A 4272/4885GAA 385/4885BCL9 3406/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | HTR2A 4272/4885GAA 385/4885BCL9 3406/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | HTR2A 4272/4885GAA 385/4885BCL9 3406/4885 |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | HTR2A 1877/4885GAA 1600/4885BCL9 2630/4885 |
| US-12162838-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | HTR2A 4272/4885GAA 385/4885BCL9 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.